Modified vaccinia virus Ankara (MVA) has been widely tested in clinical trials as
recombinant vector vaccine against infectious diseases and cancers in humans and …

Background Poxvirus-vectored vaccines against infectious diseases and cancer are
currently under development. We hypothesized that the extensive use of poxvirus-vectored …

Safety-tested modified vaccinia virus Ankara (MVA) has been established as a potent vector
system for the development of candidate recombinant vaccines. The versatility of the vector …

The production, manipulation and rescue of a bacterial artificial chromosome clone of
Vaccinia virus (VAC-BAC) in order to expedite construction of expression vectors and …

Modified vaccinia virus Ankara (MVA) is a highly attenuated and replication-deficient strain
of vaccinia virus that is increasingly used as vector for expression of recombinant genes in …

The smallpox vaccine based on the vaccinia virus was successfully used to eradicate
smallpox, but although very effective, it was a very reactogenic vaccine and responsible for …

Abstract Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation
vaccine against smallpox and serves as a potent vector system for development of new …

Recombinants based on poxviruses have been used extensively as gene delivery systems
to study many biological functions of foreign genes and as vaccines against many …

Some poxviruses are very attractive as transgenic vaccine vectors for humans, domestic
animals and wildlife. Poxviridae family members circulate in different ecosystems and parts …

Modified vaccinia virus Ankara (MVA), a widely used vaccine vector for expression of genes
of unrelated pathogens, is safe, immunogenic, and can incorporate large amounts of added …